NCT00935493

Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 154 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 75 Years
• Healthy volunteers: Accepted

Summary

This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy elderly subjects.

Detailed description

Primary: * To determine whether low does of the α2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated working memory and executive control functions, in healthy elderly subjects. Subjects will be randomly assigned to receive placebo or guanfacine at one of two dose levels: 0.1 mg, or 0.5 mg daily at bedtime in double-blind fashion for twelve weeks. Secondary: * To determine whether guanfacine can favorably influence global status and quality of life (QOL) in healthy elderly subjects. * To determine whether low-dose guanfacine is safe and well-tolerated in healthy elderly subjects.

Conditions

• Cognitive Aging

Interventions

Type	Name	Description
DRUG	Guanfacine	Guanfacine 0.1 mg po qhs
DRUG	Guanfacine	Guanfacine 0.5 mg po qhs
DRUG	Placebo	Placebo po qhs

Timeline

• Start date: 2009-06-01
• Primary completion: 2012-08-01
• Completion: 2012-08-01
• First posted: 2009-07-09
• Last updated: 2014-08-13
• Results posted: 2014-08-11

Locations

1 site across 1 country: United States